Enanta, Abbott report SVR data for interferon-free regimen

Enanta Pharmaceuticals Inc. (Cambridge, Mass.) and partner Abbott Laboratories (NYSE:ABT) reported additional data from two Phase II trials evaluating interferon-free combination regimens containing ABT-450 to treat HCV genotype 1 infection.

In the PILOT trial, all 11 evaluable treatment-naive patients receiving once-daily 150 mg ABT-450 plus ritonavir, ribavirin and ABT-072 for 12 weeks achieved and maintained HCV RNA levels less than 25 IU/mL from weeks 4-12, the primary endpoint. Additionally, 91% of patients achieved a sustained virologic response (SVR) 24 weeks after the end of treatment. ...